Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525796 · ClinicalTrials.gov registry record · Phase 2
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT02525796 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 69 participants.
The verdict
NCT02525796, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.
Interventions
- DRUG Placebo
- DRUG Cinacalcet
- DRUG eplerenone
- DRUG amiloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02525796
The ClinicalTrials.gov registry entry for NCT02525796 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02525796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02525796 about?
NCT02525796 is a clinical study titled "Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism". This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.
What is the current status of trial NCT02525796?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2016-01. Estimated completion is 2021-10-02.
What interventions are being tested in trial NCT02525796?
The interventions under investigation include: Placebo (DRUG), Cinacalcet (DRUG), eplerenone (DRUG), amiloride (DRUG).
Who is sponsoring clinical trial NCT02525796?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.